The biosimilar insulin will be sold under the brand name Semglee in a 100 IU/mL 3mL prefilled pen presentation in both territories. Mylan and Biocon say that they plans to launch the product in various markets in Europe in the second half of 2018, and in Australia “later this year.”
Mylan and Biocon have announced that their co-developed insulin glargine biosimilar, referencing Lantus, has been authorized for marketing by both the European Commission (EC), following a previous positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in January 2018, as well as by the Therapeutic Goods Administration of Australia.
The biosimilar insulin will be sold under the brand name Semglee in a 100 IU/mL 3mL prefilled pen presentation in both territories. The partnership says that it plans to launch the product in various markets in Europe in the second half of 2018, and in Australia “later this year.”
This is the first product from Mylan and Biocon’s joint portfolio to receive a marketing authorization in Europe, and Biocon’s CEO and joint managing director, Arun Chandavarkar, PhD, called the 2 approvals “important milestones” in its work with Mylan.
The partnership has also submitted the product for approval in the United States, though the drug will, if approved, follow the approval pathway for new drugs, not biosimilars; in the United States, insulins are currently regulated as drugs and not as biologics, and follow-on product sponsors must therefore submit New Drug Applications (NDAs), rather than Biologics License Applications, for these drugs.
In addition to being subject to a different approval path in the United States, Semglee also faces unique legal obstacles along the road to reach the US market; in October 2017, Sanofi, maker of the reference Lantus, sued Mylan in a New Jersey district court, saying that Mylan has infringed on 18 patents for the reference drug in developing Semglee. According to Sanofi, the Mylan NDA for Semglee included a challenge to all of Sanofi’s patents listed for Lantus in the FDA’s orange book. Then, in December 2017, Mylan announced that the United States Patent Trial and Appeal Board had instituted inter partes review proceedings against all claims of 2 patents covering Sanofi’s Lantus.
US regulatory challenges linger for the drug, as well. In February, Biocon received a Form 483 from the FDA, noting 6 observations, after a pre-approval inspection of its insulin manufacturing facility in Malaysia revealed conditions that may have constituted violations of the Food Drug and Cosmetic Act.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.
2 Commerce Drive
Cranbury, NJ 08512